Could less radiation be just as good for some throat cancers?

NCT ID NCT06239727

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether a lower dose of radiation, combined with chemotherapy and an immunotherapy drug called Camrelizumab, can control stage III nasopharyngeal cancer as well as the standard higher dose. About 593 patients whose tumors respond well to initial treatment will be randomly assigned to receive either reduced or standard radiation. The goal is to see if the lower dose reduces long-term side effects without hurting survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Camrelizumab (PD-1 blocking antibody), gemcitabine, cisplatin, and reduced-dose radiotherapy
What this could lead to: If successful, this could offer a treatment option that lowers radiation side effects while still controlling the cancer effectively.
What could go wrong: This is still an experimental approach; reduced radiation might not control the cancer as well as standard doses, and the combination with immunotherapy could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA

Contacts and locations

Locations

Affiliated Hospital of Guangdong Medical University
RECRUITING

Zhanjiang, Guangdong, China
Cancer Hospital of Guangxi Medical University
RECRUITING

Nanning, Guangxi, China
Cancer Hospital of Guizhou Medical University
RECRUITING

Guiyang, Guizhou, China
Cancer Hospital of Shantou University Medical College
RECRUITING

Shantou, Guangdong, China
Chongqing Cancer Hospital
RECRUITING

Chongqing, China
Dongguan People's Hospital
RECRUITING

Dongguan, Guangdong, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, China
Guangdong Nongken Central Hospital
RECRUITING

Zhanjiang, Guangdong, China
Hubei Province Cancer Hosiptal
RECRUITING

Wuhan, Hubei, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410000, China
Jiangsu Cancer Hospital
RECRUITING

Nanjing, Jiangsu, China
Jiangsu Provinee Hospital of Chinese Medicine
RECRUITING

Nanjing, Jiangsu, China
Jiangxi Cancer Center
RECRUITING

Nanchang, Jiangxi, China
Sichuan Cancer Hospital
RECRUITING

Chengdu, Sichuan, China
Sun Yat-Sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The Affiliated Panyu Central Hospital of Guangzhou Medical University
RECRUITING

Guangzhou, Guangdong, 511400, China
The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, China
The First Affiliated Hospital of Xian Jiaotong University
RECRUITING

Xian, Shanxi, China
The First People's Hospital of Foshan
RECRUITING

Foshan, Guangdong, 528000, China
The Second Affiliated Hospital of Hainan Medical University
RECRUITING

Haikou, Hainan, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, China
Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China
West China Hospital，Sichuan University
RECRUITING

Chengdu, Sichuan, China
Xiangya Hospital Central South University
RECRUITING

Changsha, Hunan, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.